Saving the Lives of People with Blood Cancer
by
Daniel Gibson, Head of Innovation and Commercialisation talks about the importance of securing the right material for research, and how Anthony Nolan can support pioneering researchers in sourcing it. I find it fascinating to visit researchers. I’ve had the pleasure of being shown around world class, cutting edge, multi-million-pound facilities, as well been led into…
by
Young people have a very mixed understanding of what stem cell donation involves. In this blog, Anthony Nolan’s Chief Executive Henny Braund explains how new guidelines from the Department for Education could help change this. She also reflects upon her last ten years at Anthony Nolan and the vital role that education has played in…
by
After the news that the Scottish Medicine Consortium has recommended letermovir (Prevymis) for routine use on the NHS in Scotland, Bradley from our Policy and Public Affairs team shares what this means for patients and how Anthony Nolan promoted the views and experiences of patients to help make this happen. A new preventative treatment The…
by
Jonathan in our patient services team discusses emerging treatments for cancer, using cell therapy and new ‘super cells’. When developing a new cancer treatment, one of the most important things to consider is how well it can be tolerated by patients. Often the amount of drug that can be given is limited by the side…
by
This week, the NHS released a long-term plan setting out its priorities for the service over the next ten years. This followed the government’s announcement to increase NHS funding by £20 billion a year by 2023. Please note that these plans only relate to NHS England, and the devolved nations will have control of their extra funding. Our Policy and Public Affairs Officer, Bradley Price, explains everything…
by
Jonathan in the Patient Services team discusses recent research into the use of cell therapies to treat Graft versus Host Disease (GvHD), which is a common side effect of stem cell transplant. He also looks at the implications this may have for patients whose symptoms have not responded to standard treatments. Graft vs Host…
